



**Veterinary
Medicines
Directorate**

**United Kingdom
Veterinary Medicines Directorate
Woodham Lane
New Haw
Addlestone
Surrey KT15 3LS**

NATIONAL PROCEDURE

**PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY
MEDICINAL PRODUCT**

Dormostop 5 mg/ml Solution for Injection for Dogs and Cats

Date Created: December 2023

MODULE 1

PRODUCT SUMMARY

Name, strength and pharmaceutical form	Dormostop 5 mg/ml Solution for Injection for Dogs and Cats, Solution for injection
Applicant	Alfasan Nederland B.V. Kuipersweg 9 3449 JA Woerden 3449 The Netherlands
Active substance	Atipamezole Hydrochloride
ATC Vetcode	QV03AB90
Target species	Cats Dogs
Indication for use	Reversal of the sedative effects of medetomidine and dexmedetomidine.

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Product Information Database of the Veterinary Medicines Directorate.

www.gov.uk/check-animal-medicine-licensed

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Generic application in accordance with Article 18 of Directive 2001/82/EC as amended.
Date of conclusion of the procedure	18/9/2023

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests which ensure the consistency of the product released on the market. It has been shown that the product can be safely used in the target species, any reactions observed are indicated in the SPC.¹ The product is safe for the user, and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC. The efficacy ² of the product was demonstrated according to the claims made in the SPC. The overall benefit/risk analysis is in favour of granting a marketing authorisation.

The quality / safety / efficacy aspects of this product is/are identical to Antisedan 5 mg/ml Solution for Injection. The initial application for Antisedan was assessed before there was a requirement to have a public assessment report, therefore no details in this section are available.

II. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE CONSTITUENTS

II.A. Composition

The product contains atipamezole hydrochloride and the excipients methyl parahydroxybenzoate, sodium chloride, sodium hydroxide and/or hydrochloric acid.

The container/closure system consists of a Type I glass vial closed with a rubber stopper and sealed with an aluminium cap. The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of the formulation and the presence of preservative are justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

¹ SPC – Summary of product Characteristics.

² Efficacy – The production of a desired or intended result.

II.B. Description of the Manufacturing Method

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site. The manufacturing method consists of: dissolving, stirring and filtrating.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

II.C. Control of Starting Materials

The active substance is atipamezole hydrochloride, an established active substance described in the ASMF. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

All excipients are included in the Ph. Eur.

All packaging materials are included in the Ph. Eur.

II.C.4. Substances of Biological Origin

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

II.D. Control Tests Carried Out at Intermediate Stages of the Manufacturing Process

Not applicable.

II.E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product. Satisfactory validation data for the analytical methods have been provided. Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification. Control tests on the finished product are those for: appearance, clarity, colour, pH, density and volume.

II.F. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

G. Other Information

Shelf life of the veterinary medicinal product as packaged for sale: 30 months
Shelf life after first opening the immediate packaging: 28 days

III. SAFETY AND RESIDUES DOCUMENTATION (PHARMACOTOXICOLOGICAL)

III.A Safety Documentation

Pharmacological Studies

Not required due to the legal basis of the application.

Toxicological Studies

Not required due to the legal basis of the application.

User Safety

A user risk assessment was provided in compliance with the relevant guideline.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product. Therefore the following applicant's user recommendations are appropriate:

This product may cause irritation to the skin, eyes and mucous membranes. Dermal and ocular exposure should therefore be avoided. In case of accidental dermal or ocular exposure, rinse the skin and/or the eye with water. Seek medical attention if irritation persists and show the package leaflet to the physician.

This product causes adrenergic effects. Care should be taken to avoid accidental self-injection. In case of accidental self-injection, seek medical advice immediately and show the package leaflet to the physician. Wash hands after use.

Environmental Safety

The Environmental Risk Assessment (ERA) was carried out in accordance with VICH and CVMP guidelines.

Phase I:

The product will only be used in companion animals and as a result environmental exposure will be low. A Phase II ERA was not required.

IV. CLINICAL DOCUMENTATION

IV.I. Pre-Clinical Studies

Not required due to the legal basis of the application.

IV.II. Clinical Documentation

Not required due to the legal basis of the application.

V OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that the benefit/risk profile of the product is favourable.

MODULE 4

POST- AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)

The post-authorisation assessment (PAA) contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

The PAA for this product is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)